• Publications
  • Influence
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2bExpand
  • 3,448
  • 88
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, theseExpand
  • 1,202
  • 61
  • Open Access
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitorExpand
  • 1,022
  • 41
  • Open Access
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
BACKGROUND Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmetExpand
  • 1,199
  • 36
  • Open Access
Hepatitis C virus infection in USA: an estimate of true prevalence
The recent National Health and Nutrition Examination Survey (NHANES) sampled only the civilian, non‐institutionalized population of USA and may have underestimated the prevalence of hepatitis C virusExpand
  • 376
  • 33
  • Open Access
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
BACKGROUND & AIMS There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS In this phase 2, open-label study, weExpand
  • 617
  • 31
  • Open Access
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
BACKGROUND As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS We conducted a phase 3,Expand
  • 521
  • 30
  • Open Access
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
Chronic HBV infection is an important public health problem worldwide and in the United States. A treatment algorithm for the management of this disease, published previously by a panel of U.S.Expand
  • 536
  • 28
  • Open Access
Lamivudine as initial treatment for chronic hepatitis B in the United States.
BACKGROUND AND METHODS Although the nucleoside analogue lamivudine has shown promise in patients with chronic hepatitis B, long-term data on patients from the United States are lacking. We randomlyExpand
  • 1,320
  • 25
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
BACKGROUND Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct‐acting antiviralExpand
  • 299
  • 24
  • Open Access